Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series.
P R Casson, M S Lindsay, M D Pisarska...
https://pubmed.ncbi.nlm.nih.gov/11006185Actively Recruiting
Phase 2
Phase 3
Age: 18Years - 35Years
FEMALE
ID07323329
Effect of Growth Hormone and Dehydroepiandrosterone on Poor Ovarian Reserve in Women Undergoing In Vitro Fertilization
Led by Beni-Suef University · Updated on 2026-01-07
165
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve and the outcome of intracytoplasmic sperm injection (ICSI) in women who respond poorly to ovarian stimulation. This study aims to determine which treatment is more effective at increasing the number and size of follicles, which are important for successful fertilization and pregnancy in infertility treatment. The trial is conducted by Beni-Suef University and includes women aged 18 to 35 years with poor ovarian response. Participants are randomly assigned to one of three groups: one receiving Somatropin injections of 4 IU every 3 days for at least 1 month along with daily folic acid; another receiving DHEA 50 mg twice daily for 12 weeks plus daily folic acid; and a control group receiving standard care with folic acid only. The treatment periods vary, with Somatropin given for about 1 month and DHEA for 12 weeks, followed by an ICSI cycle to assess treatment effects. During the study, participants are followed for 12 weeks while undergoing their assigned treatments and the ICSI procedure. Researchers will measure the number of mature eggs collected after treatment and monitor pregnancy rates as secondary outcomes. These assessments help determine how well each intervention supports ovarian function and fertility. The total study duration includes the treatment period and follow-up through the assisted reproduction cycle.
CONDITIONS
Brief Title
Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization
Who Can Participate
Age: 18Years - 35Years
FEMALE
Eligibility Criteria
You may qualify if you...
- Women aged 18 to 35 years
- At least two of these: advanced maternal age (>40 years) or other poor ovarian response risk factors
- 3 or fewer oocytes with a conventional stimulation protocol
- Abnormal ovarian reserve test (antral follicle count less than 5-7 follicles or anti-Müllerian hormone below 0.5-1.1 ng/ml)
You will not qualify if you...
- Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes, or thyroid dysfunction
- Any pelvic pathology such as hydrosalpinx or uterine anomaly
- Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 12 weeks
Participants receive assigned treatments including Somatropin injections every 3 days for at least 1 month, dehydroepiandrosterone twice daily for 12 weeks, or folic acid daily as standard care.
Regular visits during treatment period
Trial Site Locations
Total: 1 location
1
Beni-Suef University Hospital
Banī Suwayf, Beni Suweif Governorate, Egypt, 62521
Actively Recruiting
Loading map...
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here